Medidata Solutions (MDSO) Given a $82.00 Price Target by Royal Bank of Canada Analysts
Medidata Solutions (NASDAQ:MDSO) received a $82.00 price objective from Royal Bank of Canada in a report issued on Thursday. The brokerage currently has a “hold” rating on the stock. Royal Bank of Canada’s target price points to a potential upside of 26.21% from the stock’s current price.
MDSO has been the subject of a number of other research reports. SunTrust Banks restated a “buy” rating and issued a $92.00 target price on shares of Medidata Solutions in a research note on Friday, October 27th. Deutsche Bank began coverage on Medidata Solutions in a research note on Friday, December 8th. They issued a “buy” rating and a $78.00 target price for the company. BidaskClub upgraded Medidata Solutions from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th. TheStreet lowered Medidata Solutions from a “b” rating to a “c+” rating in a research note on Thursday, December 14th. Finally, Zacks Investment Research upgraded Medidata Solutions from a “sell” rating to a “hold” rating in a research note on Friday, November 10th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have given a buy rating to the company. Medidata Solutions currently has an average rating of “Buy” and a consensus target price of $83.00.
Medidata Solutions (NASDAQ MDSO) opened at $64.97 on Thursday. The stock has a market capitalization of $3,880.64, a price-to-earnings ratio of 92.82, a P/E/G ratio of 3.44 and a beta of 1.58. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.29 and a quick ratio of 3.37. Medidata Solutions has a 52 week low of $54.36 and a 52 week high of $85.92.
In other Medidata Solutions news, CFO Rouven Bergmann sold 2,000 shares of the stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $65.40, for a total transaction of $130,800.00. Following the sale, the chief financial officer now directly owns 91,775 shares of the company’s stock, valued at approximately $6,002,085. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Carlos Dominguez sold 9,066 shares of the stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $66.85, for a total value of $606,062.10. Following the sale, the director now directly owns 66,020 shares in the company, valued at $4,413,437. The disclosure for this sale can be found here. Insiders have sold a total of 29,010 shares of company stock worth $1,962,206 over the last ninety days. 5.80% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in MDSO. UBS Asset Management Americas Inc. grew its position in Medidata Solutions by 8.1% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 32,136 shares of the company’s stock worth $2,513,000 after purchasing an additional 2,412 shares during the period. GSA Capital Partners LLP acquired a new stake in Medidata Solutions during the 2nd quarter worth about $260,000. Ark Investment Management LLC grew its position in Medidata Solutions by 696.2% during the 2nd quarter. Ark Investment Management LLC now owns 74,769 shares of the company’s stock worth $5,847,000 after purchasing an additional 65,378 shares during the period. Parametric Portfolio Associates LLC grew its position in shares of Medidata Solutions by 25.0% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 114,468 shares of the company’s stock valued at $8,951,000 after acquiring an additional 22,892 shares during the period. Finally, Virtu KCG Holdings LLC acquired a new stake in shares of Medidata Solutions during the 2nd quarter valued at about $286,000. 97.52% of the stock is currently owned by institutional investors.
Medidata Solutions Company Profile
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.